PUBLICATION

Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo

Authors
Kucinski, J., Tallan, A., Taslim, C., Vontell, A.M., Silvius, K.M., Wang, M., Cannon, M.V., Stanton, B.Z., Kendall, G.C.
ID
ZDB-PUB-250705-12
Date
2025
Source
Cell Reports   44: 115923115923 (Journal)
Registered Authors
Kendall, Genevieve
Keywords
CP: Cancer, chromatin biology, functional epigenomics, fusion oncogenes, pediatric sarcoma, pioneer factors, rhabdomyosarcoma, zebrafish cancer models
Datasets
GEO:GSE270315, GEO:GSE270319, GEO:GSE270325
MeSH Terms
  • PAX3 Transcription Factor/genetics
  • PAX3 Transcription Factor/metabolism
  • Humans
  • Forkhead Box Protein O1/genetics
  • Forkhead Box Protein O1/metabolism
  • Oncogene Proteins, Fusion*/genetics
  • Oncogene Proteins, Fusion*/metabolism
  • Chromatin/metabolism
  • Gene Expression Regulation, Neoplastic
  • Paired Box Transcription Factors/genetics
  • Paired Box Transcription Factors/metabolism
  • Animals
  • Rhabdomyosarcoma*/genetics
  • Rhabdomyosarcoma*/metabolism
  • Rhabdomyosarcoma*/pathology
  • Zebrafish/metabolism
PubMed
40614256 Full text @ Cell Rep.
Abstract
Fusion-positive rhabdomyosarcoma is an aggressive pediatric cancer molecularly characterized by arrested myogenesis. The defining genetic driver, PAX3::FOXO1, encodes a chimeric gain-of-function transcription factor. An incomplete understanding of the in vivo chromatin regulatory mechanisms of PAX3::FOXO1 has hindered therapeutic development. Here, we establish a PAX3::FOXO1 zebrafish injection model and a semi-automated ChIP-seq normalization strategy to evaluate how PAX3::FOXO1 initially interfaces with and modulates chromatin in a developmental context. We find that PAX3::FOXO1 interacts with inaccessible chromatin through partial/homeobox motif recognition consistent with pioneering activity. However, PAX3::FOXO1-genome binding through a composite paired box/homeobox motif alters chromatin accessibility and redistributes H3K27ac to activate neural transcriptional programs. We uncover neural signatures that are highly representative of clinical rhabdomyosarcoma gene expression programs that are enriched following chemotherapy. Overall, we identify partial/homeobox motif recognition as a key mode for PAX3::FOXO1 pioneer function and identify neural signatures as a potentially critical PAX3::FOXO1 tumor initiation event.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping